Surveillance Among Healthcare Workers for SARS-Coronavirus-2 Infection

Farzanah Laher1 site in 1 country512 target enrollmentApril 22, 2020

ConditionsCOVID-19 SARS-CoV2 Infection

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: COVID-19
Sponsor: Farzanah Laher
Enrollment: 512
Locations: 1
Primary Endpoint: To determine the prevalence of symptomatic and asymptomatic SARS-CoV-2 infections among HCW.
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to investigate the epidemiology of SARS-CoV-2 infection among: i) HCW who triage patients with suspected SARS-CoV-2 infection and provide care to COVID-19 patients; and ii) laboratory personnel who test clinical samples for SARS-CoV-2 infection. After the second wave of the pandemic enrolment will be widen to any person working at the study hospitals.

Registry

clinicaltrials.gov

Start Date

April 22, 2020

End Date

April 30, 2022

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Farzanah Laher

Responsible Party

Sponsor Investigator

Principal Investigator

Farzanah Laher

University of Witwatersrand, South Africa

Eligibility Criteria

Inclusion Criteria

•HCWs of any staff category at the study hospitals.

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

To determine the prevalence of symptomatic and asymptomatic SARS-CoV-2 infections among HCW.

Time Frame: 2020

To determine the prevalence of symptomatic and asymptomatic PCR-confirmed SARS-CoV-2 infections among HCW using a systematic sampling strategy, coupled with investigation when clinically indicated.

Secondary Outcomes

To define the duration of viral "shedding".(2020)
To do sero-epidemiology assessment.(2022)
To analyse immune responses to SARS-CoV-2 infection.(2022)
To investigate the possibility of viral re-infection in this population during the study period.(2022)
To establish if common cold coronaviruses (CCCV) immunity confers protection against SARS-CoV-2 infection or disease severity(2022)
To evaluate COVID-19 vaccine effectiveness (VE) amongst HCWs, against any PCR-confirmed SARS-CoV-2 infection.(2022)
To measure humoral and cell mediated immune responses to COVID-19 vaccines stratified by previous SARS-CoV-2 infection.(2022)